New cancer drug combo tested in chinese patients
NCT ID NCT05514132
Summary
This early-stage study is testing the safety and side effects of combining two cancer drugs, ceralasertib and durvalumab, in Chinese patients with advanced solid tumors. The trial involves 14 participants who have already tried standard treatments that didn't work. Researchers will monitor how patients tolerate the drug combination and how the body processes the medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100021, China
-
Research Site
Shandong, China
Conditions
Explore the condition pages connected to this study.